CORTOSS(R) Podium Presentation at 2008 ASSR Meeting.

MALVERN, Pa. -- Orthovita, Inc. (NASDAQ:VITA), a spine and orthopedic biosurgery company, today announced an upcoming podium presentation related to its CORTOSS Bone Augmentation Material. The presentation will be held at the 2008 Annual Meeting of the American Society of Spine Radiology held in Indian Wells, California, from February 21 through 24, 2008.

Louis A. Gilula, M.D., Professor of Radiology and Orthopaedics at Washington University School of Medicine in St. Louis, will present a paper entitled, "Fill Volumes in Vertebroplasty: Observations in a Prospective Randomized IDE Study Comparing CORTOSS and PMMA."

The presentation is based on the data of 68 patients treated and followed by Professor Gilula and Dr. Paul Hatten of Vero Beach, Florida, as part of a larger 256-patient Investigational Device Study conducted for regulatory submission by Orthovita to the FDA for the use of CORTOSS in vertebral augmentation.

"Regarding clinical benefits, CORTOSS and polymethylmethacrylate performed equivalently. Interestingly, we found that the volume of material that is needed to achieve those clinical benefits for CORTOSS was half as much as for PMMA," Professor Gilula said. "The lower volume has the potential to reduce the incidence of pulmonary emboli, which, although rare, are the most common adverse events seen in vertebroplasty procedures."

The podium presentation is scheduled for February 21, 2008, at 1:15 pm PT, in the Crystal Ballroom D-F of the Renaissance Esmeralda Resort in Indian Wells.

About the Company

Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS([R]) Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based bone material, and VITAGEL([R]) Surgical Hemostat, which is an adherent matrix and an impermeable barrier to blood flow. Our longer-term U.S. clinical development program is focused on our internally developed CORTOSS([R]) Bone Augmentation Material technology platform, which is primarily designed for injections in osteoporotic spines to treat vertebral compression fractures. We work jointly with Kensey Nash Corporation to develop and commercialize novel synthetic-based biomaterial products, we market VITAGEL under a license granted by Angiotech Pharmaceuticals, Inc., and we continue to pursue similar relationships with other companies in biomaterials.

Disclosure Notice

This press release may contain forward-looking statements regarding Orthovita's current expectations of future events that involve risks and uncertainties, including, without limitation, the development, regulatory approval, demand and market acceptance of our products; our ability to obtain FDA clearance for CORTOSS in the United States; and other aspects of our business. Such statements are based on management's current expectations and are subject to a number of substantial risks and uncertainties that could cause actual results or timeliness to differ materially from those addressed in the forward-looking statements. Other factors that may cause such a difference are listed from time to time in reports filed by the Company with the U.S. Securities and Exchange Commission (SEC), including but not limited to risks described in our most recently filed Form 10-K under the caption "Risks Factors". Further information about these and other relevant risks and uncertainties may be found in Orthovita's filings with the SEC, all of which are available from the SEC as well as other sources. Orthovita undertakes no obligation to publicly update any forward-looking statements.